Actually it would be the biggest possible vindication of the tech. If Illumina bought in the share price would fly. |
NON-DILUTIVE FUNDING POTENTIAL
I would also repeat that recently FAB a £4m cap got £6m from UK Govt Future Medicines Initiative
The Labour Government wants to encourage growth
Why not throw money at a World leading technology validated by UK Global Pharma AstraZeneca and US Global DNA diagnostics firm Illumina ?
Now is the time for UK Government to provide stimulus which will have massive MULTIPLIER effects for Jobs, GDP and Growth as well as huge Health benefits
free stock charts from uk.advfn.com |
That makes no sense whatsoever. Why would that be any different to a placing - except existing holders wouldn't be able to avoid dilution - it would actually be worse than a placing! |
If Illumina took an equity stake ( vía an issue of new shares ) then there would be no need for a placing. |
Indeed - let's leave it there and keep it on topic. Should be an interesting few months ahead. |
Krypton,
Indeed.
Nigel,
Based on his input on Apta he has no idea when it comes to assessment of value. He does not understand a balance sheet, financial statements, formal announcements, business strategy etc - nothing. All he does is excerpt some figures from a results announcement, misconstrues the same (deliberately or inadvertently) then shouts placing/administration. When his thesis is repudiated he does not respind and continues to persist posting the same comment indefinitely asking posters to respond - the cycle continues.
Angle will likely need a placing at some point this year and I have so opined previously. However, it could conceivably at any point announce the next phase of the AZ deal or a partnership with Illumina that could lead to the shares doubling overnight. zIf it were to do a placing at say, 25p, I doubt current buyers would be disenchanted.
Anyway, that is the last comment from me on that clown.
Back to Angle. |
Nigelpm. Just forget about trying to justify yourself. The morons have no interest in anything but hate and vindictiveness. Woe betide anybody who suggests that things may not be as they seem. |
If his track record is anything to go by we're looking at a 200% rise from here
sent from my iPhone |
I didn't say he was a serious investor and I have no idea what he does in his spare time - my reference was simply to the evidence I had seen before my eyes of his posts on the POLX board which were spot on. |
Nigel,
Would a serious investor be driving an ambulance? Really?
That tells you all you need to know. |
I refuse to believe that there is anyone left who doesn't have PATT filtered. |
I just see it as it is Yas without the "benefit" of seeing other threads such as APTA. He warned and warned people about POLX and was spot on. The was my evidence of PATT - in other words very good. |
I always welcome bearish analysis on any thread but this guy just regurgitates the same line about an imminent placingg on every share - when one offers a rebuttal to his ‘analysis̵7; he simply ignores it and repeats the same guff. That is not constructive analysis in any sense just cut and paste.
Of course most smallcaps require placings and Angle will likely need at least one more even with extensions of existing and/or further partnerships but this clown does not grasp the overall picture. Time to ignore the clown and he will disappear when he does not get the attention he deserves, as was the case at apta.
His travk record is of shouting placing but generally in Co’s which then go on to multiply several fold. Hopeless, utterly hopeless.
I only elaborated on his guff because Nigel attached some credibility to him which is certainly unjustified given Patt’s woeful track record and cut and paste placing imminent on every share. |
POLX was a basket case - this....definitely not but I'm still undecided whether they can get the commercial traction. |
Will be very interesting. Fair enough Nigelpm. I’ve said my part. Now time to see how it turns out. Like with POLX there are some very strong believers here! |
Indeed - you've made your points PATT - time to leave it alone now. |
I'm looking forward to the Webinar where Anne Jimenez R&D Senior Director Angle Plc will speak alongside Anna Babayan Senior Marketing Manager Illumina |
'Illumina has dedicated their ENTIRE European Association for Cancer Research (EACR) webinar to ANGLE’s findings. I think that demonstrates a strong indication of their significant interest.'
If Illumina are happy with the end results...then it looks as if this is where AGL will end up. |
Radderssandy….from their own write up.
“Overall, dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care. “
Does this sound like a contract about to be written moment? Because that is what AGL needs right now. |
Ok you've made your point countless times.Point made. Move on. A better share awaits you |
PATT “Why is it that only AGL have commented on this amazing exciting development? Why is there no quote from Illumina?….221;
Illumina has dedicated their ENTIRE European Association for Cancer Research (EACR) webinar to ANGLE’s findings. I think that demonstrates a strong indication of their significant interest. |
Berenberg reissued their 40p target last week I saw I see 23p as next leg up.Patt. You're on here too often with your negative messages. Get a new share to invest in |
Last weekend I correctly predicted the share price would move strongly towards 17p
Now I predict we finish in the 20's by Fridays close
sent from my iPhone |
Very true yasX
Some are unable to grasp the potential here
It's the potential that drives the share price in early stage biotech companies
Not revenues and profits
sent from my iPhone |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
